Business Context and Reporting Period
Company: Henry Schein, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 27, 2009
Business Overview: Henry Schein is a leading distributor of healthcare products and services to office-based practitioners, including dental, medical, and animal health clinics. The company operates through two reportable segments: Healthcare Distribution and Technology. It serves over 575,000 customers globally with operations in the U.S., Canada, and 21 other countries.
Key Financial Metrics
| Metric (in thousands) | Six Months Ended June 27, 2009 |
Six Months Ended June 28, 2008 |
|---|---|---|
| Net Sales | $3,099,611 | $3,162,628 |
| Gross Profit | $919,522 | $938,741 |
| Gross Margin | 29.7% | 29.7% |
| Operating Income | $213,197 | $199,267 |
| Net Income (Total) | $139,728 | $126,391 |
| Net Income Attributable to Henry Schein | $128,324 | $116,010 |
| Diluted EPS (Henry Schein) | $1.43 | $1.26 |
| Cash from Operating Activities | $79,575 | $138,684 |
| Cash and Cash Equivalents (End of Period) | $393,873 | $271,432 |
| Total Debt | $417,494 | $417,989 |
| Working Capital | $1,031,678 | $882,401 |
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased by 2.0% ($63.0 million) compared to the prior year. This was driven by a 7.4% negative impact from foreign currency exchange, which offset 5.4% local currency growth (comprising 0.5% internal growth and 4.9% from acquisitions).
- Segment Performance:
- Healthcare Distribution: Sales declined 2.1%. Dental sales fell 3.8% due to a decline in equipment sales, while Medical sales increased 3.3% (partially driven by H1N1-related product demand). International sales dropped 3.4% due to significant currency headwinds (-18.1%) despite strong local currency growth (+14.7%).
- Technology: Sales increased 3.7% due to 8.0% internal growth, partially offset by currency impacts.
- Profitability Improvement: Despite lower sales, Operating Income increased 7.0% to $213.2 million. This was achieved through a 5.0% reduction in Selling, General, and Administrative (SG&A) expenses ($37.2 million decrease), driven by cost-cutting initiatives and favorable foreign exchange effects.
- Cash Flow Volatility: Operating cash flow decreased significantly by $59.1 million to $79.6 million. Management attributed this primarily to the timing of vendor payments early in the year, which unfavorably impacted cash flow by approximately $40 million to $50 million.
- Restructuring: The company recorded $4.0 million in restructuring costs for the six-month period, related to a plan announced in late 2008 to eliminate 430 positions and close facilities. Expected annual pretax savings from this initiative range from $24.0 million to $27.0 million.
Outlook, Risks, and Contingencies
- Liquidity and Capital Resources: The company maintains strong liquidity with $393.9 million in cash and a $400.0 million revolving credit facility (with no borrowings outstanding as of June 27, 2009). Management believes current resources are sufficient to meet short-term and long-term needs.
- Auction-Rate Securities (ARS): Approximately $27.0 million (net of temporary impairments: $24.0 million) is invested in ARS. Due to market failures since February 2008, these assets are illiquid and cannot be liquidated in the near term. However, the company continues to receive interest payments and does not anticipate defaults.
- Convertible Debt: The company holds $240.0 million in 3.0% convertible senior notes due in 2034. As of the reporting date, the notes were not convertible at a premium. The company has sufficient funds to satisfy cash conversion obligations if triggered.
- Stock Repurchases: No common stock was repurchased during the quarter. Approximately $57.7 million remains available under the current repurchase program.
- Market Risks: Key risks include the impact of the economic environment on customer demand, foreign currency fluctuations, and potential changes in healthcare regulations and reimbursement rates. The company utilizes derivative instruments to hedge interest rate and foreign currency risks.
Investor Verification Checklist
- Working Capital Timing: Verify the impact of early vendor payments on the significant year-over-year decline in operating cash flow.
- ARS Liquidity: Monitor the status of the $27.0 million investment in auction-rate securities and any potential further impairments or liquidity events.
- Foreign Currency Impact: Assess the sensitivity of future earnings to foreign exchange rates, given the substantial negative impact (-7.4% to -18.1% in segments) on reported sales growth.
- Restructuring Execution: Track the realization of the projected $24.0 million to $27.0 million in annual cost savings from the ongoing restructuring plan.
- Convertible Debt Terms: Review the conversion triggers for the $240.0 million convertible notes, specifically the stock price thresholds required for conversion.